Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 61

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 61
---
               | — |        |                                     |       — |         |     |       — |                 |     |       — |     |                                                                |   |        |     |      — |     |   |         |     |      — |     |   |     |  53,312 |     |                                |   |     |           | 1,995,468 |                                                  |   |
| 3/21/2024(5)        |     |               |               | — |        |                                     |       — |         |     |       — |                 |     |   2,221 |     |                                                                |   |        |     |  8,885 |     |   |         |     | 15,548 |     |   |     |       — |     |                                |   |     |           |   332,566 |                                                  |   |
| 3/21/2024(6)        |     |               |               | — |        |                                     |       — |         |     |       — |                 |     |   4,442 |     |                                                                |   |        |     |  8,885 |     |   |         |     | 17,770 |     |   |     |       — |     |                                |   |     |           |   398,048 |                                                  |   |

(1) The vesting schedule applicable to each equity award is set forth in the “—Outstanding Equity Awards as of December 31, 2024” table below.

(2) Amounts represent the threshold, target and maximum amounts potentially payable under our 2024 Annual Incentive Plan, as described in "Compensation Discussion and Analysis—Annual Incentive Plan" above.

(3) Amounts represent the threshold, target and maximum number of shares that may be earned under the PSUs granted in 2024, as described in "Compensation Discussion and Analysis—Equity Awards" above.

(4) The amounts shown represent the grant date fair value of the equity awards granted to our NEOs in fiscal year 2024, as computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. For purposes of our PSUs, which vest based on the attainment of certain relative total stockholder return metrics and two-year revenue CAGR (as further described above), the grant date fair value included is based on the probable achievement of such metrics. For